Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Diehl

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
Biochemistry|December 10, 1999
Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2K Jarnagin, D Grunberger, M Mulkins, et al.
Leukemia|July 9, 2010
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cellsY M Mowery, J B Weinberg, M N Kennedy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2018
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancerS Kruger, V Heinemann, C Ross, et al.
Leukemia|September 12, 2008
Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemiaJ B Weinberg, A D Volkheimer, M Mihovilovic, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemiaDaphne R Friedman, J Brice Weinberg, William T Barry, et al.
Leukemia & Lymphoma|August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemiaMark C Lanasa, Patricia H Davis, Michael Datto, et al.
Leukemia|August 3, 2021
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapyYana Pikman, Nicole Ocasio-Martinez, Gabriela Alexe, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myelomaCristina Gasparetto, Jon P Gockerman, Louis F Diehl, et al.
American Journal of Hematology|July 27, 2007
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaJ Brice Weinberg, Alicia D Volkheimer, Youwei Chen, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Biochemistry|December 10, 1999
Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2K Jarnagin, D Grunberger, M Mulkins, et al.
Leukemia|July 9, 2010
LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cellsY M Mowery, J B Weinberg, M N Kennedy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2018
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancerS Kruger, V Heinemann, C Ross, et al.
Leukemia|September 12, 2008
Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemiaJ B Weinberg, A D Volkheimer, M Mihovilovic, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2009
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemiaDaphne R Friedman, J Brice Weinberg, William T Barry, et al.
Leukemia & Lymphoma|August 11, 2011
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemiaMark C Lanasa, Patricia H Davis, Michael Datto, et al.
Leukemia|August 3, 2021
Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapyYana Pikman, Nicole Ocasio-Martinez, Gabriela Alexe, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2009
"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myelomaCristina Gasparetto, Jon P Gockerman, Louis F Diehl, et al.
American Journal of Hematology|July 27, 2007
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemiaJ Brice Weinberg, Alicia D Volkheimer, Youwei Chen, et al.
Pageof 13